Hyperhidrosis Treatment Market

Increased Prevalence of Secondary Hyperhidrosis Drive Growth of Hyperhidrosis Treatment Market

The Hyperhidrosis Treatment Market is valued at USD 734.5  Mn in 2026 and is projected to reach USD 1075.5  Mn,  growing at a CAGR of 6% by 2033.The global hyperhidrosis treatment market is expected to grow significantly over the forecast period due to an increase in secondary hyperhidrosis cases worldwide. Secondary hyperhidrosis is becoming more common as a result of sedentary lifestyles, unhealthy diets, and alcohol habits, which cause a variety of diseased conditions such as hypoglycaemia, hyperthyroidism, and anxiety. Although cases are uncommon, there are several types of secondary hyperhidrosis. For instance, gustatory sweating is a condition in which facial sweating occurs in response to food consumption. Similarly, Frey Syndrome is characterised by abnormal regeneration of damaged parasympathetic fibres that have been destroyed by a parotid or salivary tumour or surgical resection of a tumour.

Treatment adoption will increase due to the high prevalence of primary and secondary hyperhidrosis. According to a research report titled "Hyperhidrosis" released in October 2021 in the United States National Library of Medicine, it affects roughly 3% of the US population and is most common in people aged 20 to 60. The high incidence has resulted in a 20% increase in the use of over-the-counter aluminium chloride hexahydrate in the country. As a result of its predominance, product consumer demand will rise, resulting in market expansion.

To establish a strong presence and expand their geographical reach, market players use inorganic and organic strategies such as expansions, product launches, acquisitions, collaborations, mergers, and partnerships. For instance, in April 2021, Fortress Biotech and its partner company Journey Medical entered into a definitive agreement to acquire Qbrexza (glycopyrronium) in the US from Dermira, an Eli Lilly wholly-owned subsidiary. Similarly, BOTOX, manufactured by Allergan Inc, is the most researched botulinum toxin in the world. Some of the medications under clinical trials for the treatment of hyperhidrosis include Revance Therapeutics Inc's RT002 and Brickell Biotech Inc's Sofpironium Bromide, a topical anticholinergic. As a result of these factors, the studied market is expected to grow.

Long-Lasting Effects of Botulinum Toxin A to Enhance Hyperhidrosis Treatment Growth

Botox's effectiveness in treating hyperhidrosis, as well as its long-lasting effects, are driving the market growth. Botulinum toxin type A is a non-invasive surgical treatment for focal hyperhidrosis that lasts longer than topical treatments. Injections of botulinum toxin are most commonly used to treat axillary hyperhidrosis, but they can also be used to treat palmar and plantar disease. Botulinum toxin's effects last six to nine months on average, and treatment is associated with a high level of patient satisfaction. Botulinum toxin A can be used to treat excessive sweating in the armpits, hands, feet, head and face (craniofacial), and other small body areas (such as under the breasts).

Increasing Primary Hyperhidrosis Burden to Drive Growth of North American Hyperhidrosis Treatment Market

North America is expected to dominate the overall hyperhidrosis treatment market over the forecast period. The major factors contributing to its high share include increased hyperhidrosis diagnosis rates, as well as the availability of technologically advanced and sophisticated treatment options. Increasing primary hyperhidrosis burden, cancer, and cardiovascular disorders, which increase secondary hyperhidrosis, technological advancements, and the presence of key market players in the region.

Within North America, the United States has a sizeable share of the hyperhidrosis treatment market. The availability of public and private research funds, as well as the presence of key market players in the region, a growing focus on precision medicine, and rising awareness about the availability of safer medicines are among the key factors driving the market growth for Hyperhidrosis Treatment in this region. For instance, updates to commercialise QBREXZA (glycopyrronium) cloth, an anticholinergic intended for the topical treatment of primary axillary hyperhidrosis in adult and paediatric patients, have been announced by companies including Dermira, Inc.

Furthermore, increased research and development activities for hyperhidrosis treatment products in the United States are likely to lead to increased adoption of these products, driving the market's growth in the United States. According to the article "Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomised controlled trials" published in the Journal of the American Academy of Dermatology in January 2019, Glycopyrronium tosylate (GT) applied topically on a daily basis over 4 weeks reduced sweating severity as measured by ASDD-Item 2, sweat production as measured gravimetrically, and was generally well tolerated. Such initiatives increase the number of innovative products on the market, which boosts future market growth.

Companies in the hyperhidrosis treatment market are introducing new products alongside initiation collaborations, alliances and partnership agreements. For instance, in October 2021, the Phase 3 pivotal Cardigan I and Cardigan II studies, assessed sofpironium bromide gel, 15% as a once-daily topical application in patients with primary axillary hyperhidrosis, and reported positive topline results. On the other hand, in April 2021, Fortress Biotech, a Journey Medicals partner company, entered into a definitive agreement to acquire Qbrexza (glycopyrronium) in the United States from Dermira, an Eli Lilly wholly-owned subsidiary.

A few of the players in the hyperhidrosis treatment market include 

• AbbVie Inc. / Allergan
• Brickell Biotech, Inc.
• Dermira, Inc. / Eli Lilly and Company
• GlaxoSmithKline plc
• Teva Pharmaceutical Industries Ltd.
• Reddy’s Laboratories Ltd.
• Sun Pharmaceutical Industries Ltd.
• Mylan N.V. / Viatris Inc.
• Revance Therapeutics, Inc.
• Journey Medical Corporation
• Advin Health Care
• Miramar Labs, Inc.
• Alma Lasers
• Cynosure, LLC
• Bausch Health Companies Inc.

Global Hyperhidrosis Treatment Market is Segmented as Below:

By Disease Type

• Primary Focal Hyperhidrosis
• Secondary Generalized Hyperhidrosis

By Treatment Type

• Topical Treatment
• Oral Medication
• Injectable Treatment
• Device-based Treatment
• Surgical Treatment
• Others

By Drug Class

• Anticholinergics
• Botulinum Toxin
• Beta Blockers
• Benzodiazepines
• Topical Aluminum Chloride
• Others

By Procedure

• Iontophoresis
• Botulinum Toxin Injections
• Microwave Thermolysis
• Endoscopic Thoracic Sympathectomy
• Laser Therapy
• Others

By Route of Administration

• Topical
• Oral
• Injectable
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa